JP2016510810A - オレキシン受容体アンタゴニストとしてのアゼチジンアミド誘導体 - Google Patents

オレキシン受容体アンタゴニストとしてのアゼチジンアミド誘導体 Download PDF

Info

Publication number
JP2016510810A
JP2016510810A JP2015562482A JP2015562482A JP2016510810A JP 2016510810 A JP2016510810 A JP 2016510810A JP 2015562482 A JP2015562482 A JP 2015562482A JP 2015562482 A JP2015562482 A JP 2015562482A JP 2016510810 A JP2016510810 A JP 2016510810A
Authority
JP
Japan
Prior art keywords
phenyl
methyl
triazol
methanone
azetidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015562482A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510810A5 (enExample
Inventor
ボリ マーティン
ボリ マーティン
クリストフ ボス
ボス クリストフ
ブロッチ クリスティーン
ブロッチ クリスティーン
ハイドマン ビビア
ハイドマン ビビア
シファーレン ティエリー
シファーレン ティエリー
ティー ウィリアムズ ジョディ
ティー ウィリアムズ ジョディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of JP2016510810A publication Critical patent/JP2016510810A/ja
Publication of JP2016510810A5 publication Critical patent/JP2016510810A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2015562482A 2013-03-12 2014-03-11 オレキシン受容体アンタゴニストとしてのアゼチジンアミド誘導体 Pending JP2016510810A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13158791 2013-03-12
EP13158791.7 2013-03-12
PCT/IB2014/059628 WO2014141065A1 (en) 2013-03-12 2014-03-11 Azetidine amide derivatives as orexin receptor antagonists

Publications (2)

Publication Number Publication Date
JP2016510810A true JP2016510810A (ja) 2016-04-11
JP2016510810A5 JP2016510810A5 (enExample) 2017-04-06

Family

ID=47843192

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015562482A Pending JP2016510810A (ja) 2013-03-12 2014-03-11 オレキシン受容体アンタゴニストとしてのアゼチジンアミド誘導体

Country Status (7)

Country Link
US (1) US9403813B2 (enExample)
EP (1) EP2970241A1 (enExample)
JP (1) JP2016510810A (enExample)
KR (1) KR20150130413A (enExample)
CN (1) CN105051040A (enExample)
CA (1) CA2902135A1 (enExample)
WO (1) WO2014141065A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI570120B (zh) 2012-06-04 2017-02-11 艾克泰聯製藥有限公司 苯并咪唑脯胺酸衍生物
AU2013328301A1 (en) 2012-10-10 2015-05-28 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
JP6496733B2 (ja) 2013-12-03 2019-04-03 イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd (s)−(2−(6−クロロ−7−メチル−1h−ベンゾ[d]イミダゾール−2−イル)−2−メチルピロリジン−1−イル)(5−メトキシ−2−(2h−1,2,3−トリアゾール−2−イル)フェニル)メタノンの結晶形及びオレキシン受容体アンタゴニストとしてのその使用
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
KR102330133B1 (ko) 2013-12-04 2021-11-23 이도르시아 파마슈티컬스 리미티드 벤즈이미다졸-프롤린 유도체의 용도
KR102582197B1 (ko) 2017-05-03 2023-09-22 이도르시아 파마슈티컬스 리미티드 2-([1,2,3]트리아졸-2-일)-벤조산 유도체의 제조
CN109810067B (zh) * 2017-11-20 2022-05-20 扬子江药业集团有限公司 一种苏沃雷生中间体的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001247569A (ja) * 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
JP2010500401A (ja) * 2006-08-15 2010-01-07 アクテリオン ファーマシューティカルズ リミテッド アゼチジン化合物

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ253199A0 (en) 1999-08-30 1999-09-23 Fujisawa Pharmaceutical Co., Ltd. Non-prostanoid prostaglandin I2-agonist
AU2001272476A1 (en) * 2000-06-16 2001-12-24 Smithkline Beecham Plc Piperidines for use as orexin receptor antagonists
EP1353918B1 (en) 2000-11-28 2005-01-12 Smithkline Beecham Plc Morpholine derivatives as antagonists of orexin receptors
WO2002089800A2 (en) 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
CZ20032990A3 (cs) 2001-05-05 2004-04-14 Smithkline Beecham P. L. C. N-aroylové cyklické aminy
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
WO2003002561A1 (en) 2001-06-28 2003-01-09 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
DE10240818A1 (de) 2002-08-30 2004-05-13 Grünenthal GmbH Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate
WO2004026866A1 (en) 2002-09-18 2004-04-01 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
GB0225884D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
AR044586A1 (es) 2003-06-04 2005-09-21 Aventis Pharma Sa Productos aril - heteroaromaticos, composiciones que los contienen y su utilizacion
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
JP4094050B2 (ja) * 2004-03-01 2008-06-04 アクテリオン ファーマシューティカルズ リミテッド 置換1,2,3,4−テトラヒドロイソキノリン誘導体
US20050272784A1 (en) 2004-05-07 2005-12-08 Xiaobing Li Inhibitors of bacterial Type III protein secretion systems
EP1604989A1 (en) 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft DPP-IV inhibitors
US7269781B2 (en) 2004-06-25 2007-09-11 Hewlett-Packard Development Company, L.P. Discrete universal denoising with reliability information
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
GB0510142D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
HUP0500920A2 (en) 2005-10-05 2007-07-30 Richter Gedeon Nyrt Oxadiazole derivatives, process for their preparation and their use
EP1998774A1 (en) 2006-03-15 2008-12-10 Actelion Pharmaceuticals Ltd. Tetrahydroisoquinoline derivatives to enhance memory function
EP2049110B1 (en) 2006-07-14 2014-08-20 Merck Sharp & Dohme Corp. Bridged diazepan orexin receptor antagonists
CL2007002809A1 (es) 2006-09-29 2008-04-18 Actelion Pharmaceuticals Ltd Compuestos derivados de 3-aza biciclo [3.1.0]hexano; y su uso en el tratamiento de enfermedades tales como desordenes psicoticos y de ansiedad, desordenes del sueno, uso y abuso de sustancias psicoactivas, demencia y deterioro de funciones cognitivas
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
US8133901B2 (en) 2006-12-01 2012-03-13 Actelion Pharmaceuticals Ltd. 3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors
TW200833328A (en) 2006-12-28 2008-08-16 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.1.0]hexane derivatives
WO2008087611A2 (en) 2007-01-19 2008-07-24 Actelion Pharmaceuticals Ltd Pyrrolidine- and piperidine- bis-amide derivatives
CL2008000836A1 (es) 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
ES2351079T3 (es) 2007-05-14 2011-01-31 Actelion Pharmaceuticals Ltd. Derivados de 2-ciclopropil-tiazol.
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8030495B2 (en) 2007-05-23 2011-10-04 Coleman Paul J Cyclopropyl pyrrolidine orexin receptor antagonists
JP2010531871A (ja) 2007-07-03 2010-09-30 アクテリオン ファーマシューティカルズ リミテッド 3−アザ−ビシクロ[3.3.0]オクタン化合物
GB0712888D0 (en) 2007-07-03 2007-08-15 Glaxo Group Ltd Novel compounds
TW200911242A (en) 2007-07-03 2009-03-16 Glaxo Group Ltd Novel compounds
EP2185512B1 (en) 2007-07-27 2010-12-29 Actelion Pharmaceuticals Ltd. Trans-3-aza-bicyclo[3.1.0]hexane derivatives
KR20100046047A (ko) 2007-07-27 2010-05-04 액테리온 파마슈티칼 리미티드 2-아자-비시클로[3.3.0]옥탄 유도체
AR067665A1 (es) 2007-07-27 2009-10-21 Actelion Pharmaceuticals Ltd Derivados de trans-3- aza-biciclo ( 3.1.0) hexano
CA2699328A1 (en) 2007-09-24 2009-04-02 Actelion Pharmaceuticals Ltd Pyrrolidines and piperidines as orexin receptor antagonists
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
DK2225231T3 (da) 2007-12-18 2011-10-17 Actelion Pharmaceuticals Ltd Aminotriazolderivater som alx-agonister
BRPI0908096A2 (pt) 2008-02-21 2015-08-25 Actelion Pharmaceuticals Ltd Derivado de 2-aza-biciclo [2.2.1] heptano
GB0806536D0 (en) 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
CA2729985A1 (en) 2008-07-07 2010-01-14 Actelion Pharmaceuticals Ltd Thiazolidine compounds as orexin receptor antagonists
WO2010038200A1 (en) 2008-10-01 2010-04-08 Actelion Pharmaceuticals Ltd Oxazolidine compounds as orexin receptor antagonists
WO2010044054A1 (en) 2008-10-14 2010-04-22 Actelion Pharmaceuticals Ltd Phenethylamide derivatives and their heterocyclic analogues
JP2012506375A (ja) 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション 2,5−二置換ピペリジンオレキシン受容体アンタゴニスト
JP2012509910A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
EP2358712A1 (en) 2008-11-26 2011-08-24 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
EP2358713A1 (en) 2008-11-26 2011-08-24 Glaxo Group Limited Imidazopyridazine derivatives acting as orexin antagonists
TW201031407A (en) 2008-12-02 2010-09-01 Glaxo Group Ltd Novel compounds
CA2745433A1 (en) 2008-12-02 2010-06-10 Glaxo Group Ltd. N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
EP2413941A4 (en) 2009-04-03 2012-10-10 Merck Sharp & Dohme Renin Inhibitors
US20120040991A1 (en) 2009-04-24 2012-02-16 Glaxo Group Limited 3-azabicyclo [4.1.0] heptanes used as orexin antagonists
JP5095035B2 (ja) 2009-06-09 2012-12-12 アクテリオン ファーマシューティカルズ リミテッド フッ素化アミノトリアゾール誘導体
ES2585806T3 (es) 2009-10-23 2016-10-10 Janssen Pharmaceutica N.V. Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina
EP2491034B1 (en) 2009-10-23 2013-12-18 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds as orexin receptor modulators
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
US8735384B2 (en) 2010-01-19 2014-05-27 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
CA2812699A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
DK2776430T3 (en) 2011-11-08 2016-05-09 Actelion Pharmaceuticals Ltd 2- (1,2,3-triazol-2-yl) benzamide and 3- (1,2,3-triazol-2-yl) PICOLINAMIDDERIVATER AS orexin receptor antagonists
TWI570120B (zh) 2012-06-04 2017-02-11 艾克泰聯製藥有限公司 苯并咪唑脯胺酸衍生物
AU2013328301A1 (en) 2012-10-10 2015-05-28 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001247569A (ja) * 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
JP2010500401A (ja) * 2006-08-15 2010-01-07 アクテリオン ファーマシューティカルズ リミテッド アゼチジン化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BORG.S., ET AL.: "Synthesis of 1,2,4-oxadiazole-, 1,3,4-oxadiazole-, and 1,2,4-triazole-derived dipeptidomimetics", JOURNAL OF ORGANIC CHEMISTRY, vol. 60(10), JPN6017050238, 1995, pages 3112 - 3120, ISSN: 0003711037 *

Also Published As

Publication number Publication date
EP2970241A1 (en) 2016-01-20
CA2902135A1 (en) 2014-09-18
WO2014141065A1 (en) 2014-09-18
KR20150130413A (ko) 2015-11-23
US20160024064A1 (en) 2016-01-28
CN105051040A (zh) 2015-11-11
US9403813B2 (en) 2016-08-02

Similar Documents

Publication Publication Date Title
JP6244365B2 (ja) [オルトビ−(ヘテロ−)アリール]−[2−(メタビ−(ヘテロ−)アリール)−ピロリジン−1−イル]−メタノン誘導体であるオレキシン受容体アンタゴニスト
JP5814491B2 (ja) ベンズイミダゾール−プロリン誘導体
JP5718535B2 (ja) オレキシン受容体アンタゴニストとしての2−(1,2,3−トリアゾール−2−イル)ベンズアミド及び3−(1,2,3−トリアゾール−2−イル)ピコリンアミド誘導体
TWI808305B (zh) 作為法尼醇x受體調節劑之經取代雙環化合物
US9403813B2 (en) Azetidine amide derivatives as orexin receptor antagonists
EP2516437A1 (en) Disubstituted heteroaryl-fused pyridines
JP2014512347A (ja) チアゾロピリミジン化合物
JP6883045B2 (ja) オレキシン受容体調節因子としてのハロ置換ピペリジン
WO2013050938A1 (en) 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives
EP2632924A1 (en) Diaza-spiro[5.5]undecanes useful as orexin receptor antagonists
AU2013241050B2 (en) Triazinone compound and T-type calcium channel inhibitor
EA047337B1 (ru) Замещенные бициклические соединения в качестве модуляторов фарнезоидного х-рецептора

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170228

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20171228

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180801